Characteristics and Outcomes of Young Adults with Philadelphia-negative Myeloproliferative Neoplasms
Overview
Affiliations
Objective: Approximately 10% of Philadelphia (Ph)-negative myeloproliferative neoplasms (NPM) are diagnosed at young adulthood. We aim to define the features of this group.
Methods: A multicenter retrospective study, including patients 18-45 years of age, diagnosed with Ph-negative MPN between 1985 and 2017.
Results: One hundred nine patients were included, 37 with polycythemia vera (34%), 54 with essential thrombocytosis (50%), 15 with primary myelofibrosis (PMF) (14%), and 3 with MPN unclassifiable (3%). Median age was 33 years and 62 (57%) were females. During a median follow-up of 8 years, 39 patients (37%) had at least one thrombotic event. 30/39 of events were venous (77%), 23/30 of which were splanchnic (77%). In 14/39 (36%), thrombosis preceded MPN diagnosis. In a multivariable analysis, only splenomegaly predicted for thrombosis (HR 5.6, CI: 1.4-22). The 10-year risk for secondary myelofibrosis was similar for ET and PV (0.13 vs 0.19, P = 0.51). The 10-year risk for leukemic transformation or mortality was significantly higher for PMF (0.3, P = 0.04).
Conclusions: The risks of mortality and of progression to MF/leukemia in young adults are similar to older population. Thrombotic events are frequently a presenting sign with a high incidence of venous, in particular splanchnic, events.
Beauverd Y, Ianotto J, Thaw K, Sobas M, Sadjadian P, Curto-Garcia N Leukemia. 2025; .
PMID: 40074852 DOI: 10.1038/s41375-025-02545-2.
Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T Int J Hematol. 2024; 120(6):684-693.
PMID: 39467899 DOI: 10.1007/s12185-024-03862-5.
Myeloproliferative neoplasms: young patients, current data and future considerations.
Sobas M, Ianotto J, Kiladjian J, Harrison C Ann Hematol. 2024; 103(9):3287-3291.
PMID: 39110200 DOI: 10.1007/s00277-024-05920-8.
Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian J, Pemmaraju N Br J Haematol. 2024; 205(1):48-60.
PMID: 38853641 PMC: 11245372. DOI: 10.1111/bjh.19557.
England J, Szuber N, Sirhan S, Dunne T, Cerquozzi S, Hill M Leukemia. 2024; 38(3):570-578.
PMID: 38321107 DOI: 10.1038/s41375-024-02155-4.